Wharton's Jelly-Derived Mesenchymal Stem Cells in the Treatment of Four Patients with Alopecia Areata
February 2021
in “
Advances in Clinical and Experimental Medicine
”
TLDR Wharton's jelly-derived stem cells were safely used to treat four alopecia patients, resulting in hair regrowth in all of them.
The study involved four patients with alopecia areata who were treated with a single intradermal injection of Wharton’s jelly-derived mesenchymal stem cells (WJ-MSCs) into the alopecia foci. The Severity of Alopecia Tool (SALT) score was used to measure the intensity of alopecia before treatment, 12 weeks after treatment, and 24 weeks after treatment. Results showed an average hair regrowth of 67% at the injection sites, with the first 3 months showing a greater increase of 52.2% compared to the following 3 months' average of 32%. The study concluded that the therapy was safe, with no side effects, and resulted in hair growth in all participants.
